$0.43 Earnings Per Share Expected for Globus Medical Inc (NYSE:GMED) This Quarter

Brokerages expect Globus Medical Inc (NYSE:GMED) to report $0.43 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Globus Medical’s earnings. The lowest EPS estimate is $0.42 and the highest is $0.44. Globus Medical reported earnings of $0.39 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.3%. The firm is scheduled to report its next quarterly earnings report after the market closes on Wednesday, November 6th.

According to Zacks, analysts expect that Globus Medical will report full-year earnings of $1.71 per share for the current financial year, with EPS estimates ranging from $1.69 to $1.72. For the next fiscal year, analysts anticipate that the firm will post earnings of $1.90 per share, with EPS estimates ranging from $1.86 to $1.93. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Globus Medical.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.41. Globus Medical had a net margin of 19.30% and a return on equity of 13.29%. The firm had revenue of $150.55 million for the quarter, compared to analyst estimates of $184.93 million. During the same quarter in the prior year, the business posted $0.44 EPS. The business’s revenue was up 10.9% compared to the same quarter last year.

A number of research analysts have issued reports on GMED shares. Zacks Investment Research upgraded shares of Globus Medical from a “sell” rating to a “hold” rating and set a $54.00 target price on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target (up previously from $52.00) on shares of Globus Medical in a report on Friday, August 2nd. Wells Fargo & Co upped their price target on shares of Globus Medical from $42.00 to $53.00 and gave the stock a “market perform” rating in a report on Tuesday, October 8th. Finally, ValuEngine raised shares of Globus Medical from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $56.40.

Shares of NYSE:GMED remained flat at $$51.40 on Monday. 366,441 shares of the company’s stock were exchanged, compared to its average volume of 583,608. The company’s fifty day moving average price is $50.65 and its two-hundred day moving average price is $45.98. Globus Medical has a 1 year low of $38.01 and a 1 year high of $57.83. The firm has a market cap of $5.06 billion, a P/E ratio of 30.78, a price-to-earnings-growth ratio of 2.65 and a beta of 0.97.

In related news, Director David D. Davidar sold 50,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $49.33, for a total value of $2,466,500.00. Following the completion of the transaction, the director now owns 754,775 shares of the company’s stock, valued at approximately $37,233,050.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Kelly Huller sold 3,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $49.90, for a total transaction of $149,700.00. Following the completion of the transaction, the senior vice president now directly owns 9,384 shares of the company’s stock, valued at approximately $468,261.60. The disclosure for this sale can be found here. 24.97% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of GMED. Janus Henderson Group PLC lifted its stake in Globus Medical by 83.1% in the 2nd quarter. Janus Henderson Group PLC now owns 6,179,600 shares of the medical device company’s stock valued at $261,397,000 after purchasing an additional 2,803,797 shares during the last quarter. Nuance Investments LLC lifted its stake in Globus Medical by 307.4% in the 2nd quarter. Nuance Investments LLC now owns 1,316,057 shares of the medical device company’s stock valued at $55,669,000 after purchasing an additional 993,056 shares during the last quarter. Nuveen Asset Management LLC bought a new position in Globus Medical in the 2nd quarter valued at approximately $29,363,000. Pembroke Management LTD bought a new position in Globus Medical in the 2nd quarter valued at approximately $13,495,000. Finally, Invesco Ltd. lifted its stake in Globus Medical by 73.1% in the 2nd quarter. Invesco Ltd. now owns 627,072 shares of the medical device company’s stock valued at $26,526,000 after purchasing an additional 264,790 shares during the last quarter. 67.86% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on Globus Medical (GMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.